Standout Papers

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitiv... 2014 2026 2018 2022 435
  1. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study (2014)
    Joyce F. Liu, William T. Barry et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 11 from Science/Nature 59 standout
Sub-graph 1 of 21

Citing Papers

PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
2 intermediate papers

Works of Weixiu Luo being referenced

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014 Standout
Presence of Tumor-Infiltrating Lymphocytes and a Dominant Nodule Within Primary Melanoma Are Prognostic Factors for Relapse-Free Survival of Patients With Thick (T4) Primary Melanoma
2010

Author Peers

Author Last Decade Papers Cites
Weixiu Luo 646 98 414 256 17 993
Alexandra S. Zimmer 786 74 195 350 24 1.1k
Jerrold B. Teitcher 365 25 329 311 22 1.3k
Conway Gee 461 47 130 331 14 913
D. Vena 577 21 124 179 13 1.4k
Anne P.G. Crijns 267 39 135 187 32 1.1k
Martin Pölcher 305 50 364 183 37 892
Cecelia H. Boardman 429 52 345 317 21 1.2k
Shamshad Ali 241 22 427 150 21 1.4k
Elaine K. Wong 561 22 58 133 19 910
Y. Tsukada 173 46 288 151 25 1.3k

All Works

Loading papers...

Rankless by CCL
2026